Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -27.55%2.68B | -43.82%1.67B | -37.98%891.76M | -30.34%4.59B | -21.91%3.69B | 7.20%2.98B | 0.80%1.44B | 31.12%6.6B | 40.27%4.73B | 17.92%2.78B |
| Operating income | -27.55%2.68B | -43.82%1.67B | -37.98%891.76M | -30.34%4.59B | -21.91%3.69B | 7.20%2.98B | 0.80%1.44B | 31.12%6.6B | 40.27%4.73B | 17.92%2.78B |
| Operating expenses | 16.12%-3.04B | 30.48%-1.93B | 23.39%-1.01B | 17.78%-4.79B | 13.50%-3.62B | -11.61%-2.77B | -2.65%-1.32B | -31.51%-5.83B | -39.12%-4.19B | -18.15%-2.48B |
| Gross profit | -593.89%-361.16M | -221.87%-253.16M | -202.22%-119.87M | -126.18%-199.98M | -86.56%73.13M | -29.82%207.73M | -16.21%117.26M | 28.16%764M | 49.83%544.28M | 16.07%296M |
| Selling expenses | 63.78%-5.71M | 69.53%-3.54M | 67.78%-1.78M | 17.50%-16.31M | 20.30%-15.77M | 4.29%-11.61M | 27.82%-5.53M | -13.45%-19.77M | -47.93%-19.78M | -71.96%-12.14M |
| Administrative expenses | -5.38%-111.35M | 13.65%-62.55M | 17.24%-31.21M | -2.61%-150.96M | 3.03%-105.66M | -1.42%-72.43M | -6.43%-37.71M | -16.52%-147.12M | -28.80%-108.96M | -29.31%-71.42M |
| Research and development expenses | 36.48%-101.8M | 42.12%-66.85M | 51.31%-26.54M | 30.75%-174.18M | 8.47%-160.26M | -7.72%-115.51M | 6.35%-54.51M | -44.73%-251.52M | -40.10%-175.1M | -30.29%-107.23M |
| Profit from asset sales | -99.33%24.23K | -99.97%1.15K | -96.34%1.15K | -92.48%3.39M | -67.90%3.63M | 70,311.56%3.61M | 188.56%31.45K | 2,805.00%45.11M | 35,106.83%11.31M | 92.70%-5.14K |
| Impairment and provision | 25.72%-19.64M | -46.33%-43.79M | 3,605.06%62.79M | -2,134.88%-135.98M | -2,126.00%-26.45M | -1,346.47%-29.93M | -59.12%1.69M | 134.44%6.68M | 140.15%1.31M | 128.83%2.4M |
| -Other impairment is provision | 25.72%-19.64M | -46.33%-43.79M | 3,605.06%62.79M | -2,134.88%-135.98M | -2,126.00%-26.45M | -1,346.47%-29.93M | -59.12%1.69M | 134.44%6.68M | 140.15%1.31M | 128.83%2.4M |
| Special items of operating profit | 68.21%67.85M | -76.30%4.51M | -74.52%3.04M | -79.28%46.02M | -63.53%40.34M | -83.57%19.02M | 5.31%11.92M | -30.18%222.08M | -54.65%110.61M | -50.09%115.74M |
| Operating profit | -155.99%-565.54M | -2,144.59%-447.4M | -583.95%-123.72M | -216.45%-669.58M | -166.08%-220.92M | -109.81%-19.93M | -43.79%25.56M | 6.36%575M | -6.09%334.31M | -36.21%203.14M |
| Financing cost | -26.56%-84.78M | -14.47%-56.61M | -19.93%-24.83M | -49.89%-111.12M | -9.90%-66.99M | -34.80%-49.45M | -16.41%-20.7M | -0.81%-74.13M | -16.13%-60.96M | 1.32%-36.68M |
| Adjustment items of earning before tax | 271.84%676.68K | 276.64%620.66K | 53,089.71%435.2K | -114.61%-73.54K | -183.52%-393.79K | -176.25%-351.37K | -72.40%818.21 | -84.25%503.21K | -71.73%471.46K | -34.50%460.83K |
| Earning before tax | -125.33%-649.64M | -621.87%-503.38M | -3,144.83%-148.11M | -255.73%-780.77M | -205.29%-288.31M | -141.78%-69.73M | -82.44%4.86M | 6.61%501.37M | -10.27%273.82M | -40.81%166.92M |
| Tax | -105.64%-1.93M | -99.57%93.61K | 368.37%9.81M | 421.88%117.67M | 220.27%34.22M | 272.62%21.75M | 38.20%-3.65M | -229.43%-36.56M | -143.87%-28.46M | -44.94%-12.6M |
| After-tax profit from continuing operations | -156.44%-651.57M | -948.78%-503.29M | -11,535.15%-138.3M | -242.66%-663.1M | -203.55%-254.09M | -131.10%-47.99M | -94.45%1.21M | 41.93%464.82M | 51.63%245.37M | -42.44%154.32M |
| Earning after tax | -156.44%-651.57M | -948.78%-503.29M | -11,535.15%-138.3M | -242.66%-663.1M | -203.55%-254.09M | -131.10%-47.99M | -94.45%1.21M | 1.23%464.82M | -16.40%245.37M | -43.54%154.32M |
| Minority profit | -714.18%-55.31M | -899.36%-54.31M | -274.12%-13.17M | -175.85%-53.17M | -114.30%-6.79M | -73.44%6.79M | -19.06%7.56M | 39.83%70.1M | 46.16%47.51M | 0.62%25.58M |
| Profit attributable to shareholders | -141.12%-596.26M | -719.59%-448.98M | -1,869.63%-125.13M | -254.52%-609.93M | -224.98%-247.29M | -142.55%-54.78M | -151.04%-6.35M | -3.50%394.72M | -24.19%197.86M | -48.06%128.74M |
| Basic earnings per share | -142.11%-0.92 | -775.00%-0.7 | -1,800.00%-0.19 | -254.10%-0.94 | -222.58%-0.38 | -140.00%-0.08 | -151.81%-0.01 | -3.17%0.61 | -22.50%0.31 | -47.37%0.2 |
| Diluted earnings per share | -142.11%-0.92 | -775.00%-0.7 | -1,800.00%-0.19 | -254.10%-0.94 | -222.58%-0.38 | -140.00%-0.08 | -151.81%-0.01 | -3.17%0.61 | -22.50%0.31 | -47.37%0.2 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.